IL6 and prostate cancer: In prostate cancer (PCA), its overexpression modulates IL6-activation, and other miRNAs, including miR-210, miR-143, and miR-590-5p, that coherently up-modulate CAF activation. miR-133b is also released into the media and its incorporation into PCa cells, may contribute to the establishment of mesenchymal phenotype.